Skip to content

Evaluation of the effect of tranexamic acid and dexamethasone on total knee arthroplasty with tourniquet

Evaluation of the effect of tranexamic acid and dexamethasone on total knee arthroplasty with lower tourniquet

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200060567
Enrollment
Unknown
Registered
2022-06-05
Start date
2022-02-10
Completion date
Unknown
Last updated
2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis

Interventions

B:Using dexamethasone without tourniquet
C:Using dexamethasone with tourniquet

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Primary and unilateral end-stage primary or secondary knee osteoarthritis, traumatic arthritis, and patients who need TKA surgery; 2. Age 18 to 80 years old; 3. Patients who voluntarily participated in clinical trials and signed the informed consent form with good compliance.

Exclusion criteria

Exclusion criteria: 1. Preoperative CRP>10mg/L, IL-6>15pg/ml; 2. Patients with uncontrolled systemic infections such as pulmonary infection and urinary tract infection before surgery; 3. Knee flexion deformity >15 degree, varus deformity >10 degree, valgus deformity >15 degree, with obvious bone defect (AORI > type I); 4. ASA classification > grade III; 5. Use of drugs that affect the function of the coagulation system (such as aspirin, clopidogrel, ticlopidine, dipyridamole, ginkgo biloba preparations, heparin, warfarin, citrate, blood coagulation) 1 week before surgery Enzyme, Vk, antifibrinolytic, hemostatic sensitivity, Vc, etc.); 6. Those with abnormal coagulation function or thromboelastographic before surgery; 7. Clearly allergic to TXA or contraindicated; 8. Patients with old deep vein thrombosis, severe varicose veins, and arterial occlusion in the lower limbs on the affected side; 9. Patients with a history of myocardial infarction, angina pectoris, cerebral infarction and epilepsy in the past 6 months; 10. Those with hemoglobin 35kg/m2; 12. Patients who are considered unsuitable by the investigator to participate in this clinical trial.

Design outcomes

Primary

MeasureTime frame
Hemoglobin;Hematocrit;ESR;CRP;IL-6;Perioperative blood loss;

Secondary

MeasureTime frame
APTT;PT;INR;d-dimer;FDP;Range Of Motion, ROM;Hospital for special surgery score system;Limb circumference;

Countries

China

Contacts

Public ContactHuang Qiang

West China Hospital of Sichuan University

huangqiang4325@126.com+86 18980606708

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 11, 2026